Brady Todd C 4

What Happened
Todd C. Brady, President, CEO and a director of Aldeyra Therapeutics (ALDX), was granted two equity awards on March 27, 2026: 1,880,510 derivative shares (option) and 632,318 bonus units, both recorded at $0.00 per share (total listed consideration $0). These are awards/derivative grants (transaction code A), not open-market purchases or sales.

Key Details

• Transaction date: 2026-03-27; Form 4 filed 2026-03-31 (filed late relative to the 2-business-day Form 4 requirement).
• Awards: 1,880,510 option-type shares (vesting) and 632,318 bonus units; combined total = 2,512,828 derivative shares. Price reported: $0.00 (grant).
• Shares owned after transaction: Not specified in this Form 4.
• Footnote F1: The option shares vest in equal monthly installments over 48 months of continuous service starting January 1, 2026.
• Footnote F2: The bonus units vest ratably in equal annual installments over four years beginning March 27, 2026; vested bonus units are payable in cash (on the earlier of four years from grant or a Change of Control) equal to the closing market price on the payment date.
• Transaction type: Awards/derivatives (code A); not an immediate purchase or sale.

Context
These are time‑based awards that vest over multiple years and therefore do not represent immediate acquisition of freely tradeable shares. The bonus units are payable in cash upon vesting (or earlier in a change of control), so they are economically different from standard stock grants. Because the Form 4 was filed after the typical 2-business-day deadline, it is noted as late filing in the record.